With the recent announcement that a first -
line immunotherapy trial for non-small cell lung cancer (NSCLC) is positive for survival improvement, I can see the standard of care for lung cancer patients radically changing over the next few years.
«First -
line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical
trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»